|
| Wednesday, December 14, 2022 |
|
|
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the interim results of part-one of an ongoing Phase IIb clinical trial of STP705 for the treatment of Cutaneous Squamous Cell Carcinoma In Situ (isSCC). more info >> |
|
|
Sirnaomics执行董事戴晓畅博士将于2022年度香港国际生物科技展上发表主题演讲 |
| Sirnaomics Ltd.（“公司”，“Sirnaomics”，股份代号：2257. HK），是一家全球领先的、专注于探索及开发RNAi疗法的生物制药公司。 more info >> |
|
|
Sirnaomics執行董事戴曉暢博士將於2022年度香港國際生物科技展上發表主題演講 |
| Sirnaomics Ltd.（「公司」，「Sirnaomics」，股份代號：2257.HK），是一家全球領先的、專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
|
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022 |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Executive Director Dr. Xiaochang Dai will deliver a keynote speech at BIOHK2022, the first major biotech conference to be held in Hong Kong since the outbreak of the COVID-19 pandemic. more info >> |
|
| Tuesday, November 8, 2022 |
|
|
Sirnaomics已完成STP705用于成人腹部减脂医学美容治疗的首例受试者给药 |
| Sirnaomics Ltd.（“公司”，“Sirnaomics”，股份代号：2257.HK），是一家行业领先的专注于探索及开发 RNAi疗法的生物制药公司。 more info >> |
|
|
Sirnaomics已完成STP705用於成人腹部減脂醫學美容治療的首例受試者給藥 |
| Sirnaomics Ltd.（「公司」，「Sirnaomics」，股份代號：2257.HK），是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。 more info >> |
|
|
Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the Company has dosed the first patient in a Phase I clinical study of STP705, a siRNA (small interfering RNA) drug candidate, for the study of fat reduction in adults undergoing abdominoplasty. more info >> |
|
| Wednesday, October 19, 2022 |
|
|
Sirnaomics将在未来两个行业学术会议上汇报GalAhead(TM)疗法递送平台及相关项目的最新进展 |
| Sirnaomics Ltd.（“公司”，“Sirnaomics”，股份代号：2257.HK），是一家行业领先的专注于探索及开发RNAi疗法的生物制药公司。Sirnaomics宣布公司将会在波士顿举行的两个行业学术会议 more info >> |
|
|
Sirnaomics將在未來兩個行業學術會議上匯報GalAhead(TM)療法遞送平台及相關項目的最新進展 |
| Sirnaomics Ltd.（「公司」，「Sirnaomics」，股份代號：2257.HK），是一家行業領先的專注於探索及開發RNAi療法的生物製藥公司。Sirnaomics宣佈公司將會在波士頓舉行的兩個行業學術會議 more info >> |
|
|
Sirnaomics to Present Latest Developments on GalAhead(TM) Therapeutic Platform at Upcoming Industry Conferences |
| Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on GalAhead(TM), a GalNAc-RNAi therapeutic platform, and its pipeline programs, at two industry conferences in Boston more info >> |
|
|
|
|
